The failure of Takeda Pharmaceutical Co. Ltd./Zinfandel Pharmaceuticals Inc.'s Phase III TOMMORROW study – the first major trial of extremely early Alzheimer's, before symptoms are even apparent – is a disappointment for the field but doesn't mean an end to similar approaches, far from it.
The TOMMORROW study tested Takeda's PPAR-gamma agonist Actos (pioglitazone) at a low dose for delaying the onset of mild cognitive impairment